PMC:7696151 / 81687-81980
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2423 | 58-61 | Chemical | denotes | HCQ | MESH:D006886 |
| 2424 | 146-149 | Chemical | denotes | HCQ | MESH:D006886 |
| 2425 | 252-263 | Chemical | denotes | doxorubicin | MESH:D004317 |
| 2450 | 159-164 | Disease | denotes | tumor | MESH:D009369 |
| 2451 | 284-292 | Disease | denotes | melanoma | MESH:D008545 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T190 | 159-164 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
| T191 | 284-292 | Phenotype | denotes | melanoma | http://purl.obolibrary.org/obo/HP_0002861 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T523 | 0-293 | Sentence | denotes | As demonstrated by Naso, Wong, Wong, Chen and Hoang [72], HCQ liposomes (60 mg/kg), together with a pH-sensitive targeting peptide that delivered HCQ into the tumor cells and lysosomes, enhanced the chemotherapic effect of conventional anticancer drug doxorubicin in animal models of melanoma. |